1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
Posted on Tuesday, Mar 23, 2010

Completion of Endostar Phase IV Trial Hopeful for Mesothelioma Treatment

Simcere Pharmaceutical Group, a Chinese manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar, announced this week the successful completion of Endostar Phase IV clinical trial.

Since September 2005, Endostar has been approved to treat Non-Small-Cell Lung Cancer (NSCLC) in China. Endostar is a modified version of recombinant human Endostatin designed to stop the growth of cancer by starving it of oxygen and other nutrients. Endostar, also known as Endu, is the first anti-angiogenic drug in the world. Because mesothelioma cells rely on a large number of blood vessels to grow, researchers believe that Endostatin will be an effective treatment for mesothelioma and other fast-growing cancers.

Mesothelioma, an unusual form of cancer which can take up to five decades to be properly diagnosed, is responsible for approximately 3,000 new cases each year in the United States. Although there is no cure for mesothelioma, it can be treated with varying degrees of success through the use of surgical procedures, chemotherapy and radiation.

The findings of the clinical study verified that by combining Endostar with standard chemotherapy regimens the treatment could improve the median survival time and overall survival rate of patients with advanced NSCLC with no significant increase of the adverse effects of chemotherapy.